← 返回

原发性肝癌中的三级淋巴结构:争议无法掩盖希望

英文原题:Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope.

查看英文原题

Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope.

PubMed 2022/06/29(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

三级淋巴结构(TLS)是肿瘤微环境中由免疫细胞构成的有组织聚集体。TLS可影响原发性肝癌(PHC)的发生并参与癌症进程。其位置不同,对PHC生长的作用可能促进或抑制;尽管现有发现相互矛盾,但总体提示TLS在PHC组织中可能发挥保护作用,而在癌旁组织中则未必有保护效应。此外,TLS细胞组成也会影响PHC结局。作为免疫标志物,TLS可用于预测免疫治疗效果并帮助识别可能应答的患者。研究者已在PHC及其他癌症中广泛研究利用趋化因子/细胞因子、免疫治疗或诱导高内皮微静脉调节TLS形成以干预肿瘤生长。此外,基因干预、细胞间相互作用、术前放疗及材料科学进展等新方法,也显示可通过调节TLS生成影响恶性肿瘤预后,并可用于开发PHC治疗方案。

展开英文摘要原文

Tertiary lymphoid structures (TLSs) are organized aggregates of immune cells found in the tumor microenvironment. TLS can influence primary hepatic carcinoma (PHC) occurrence and have an active role in cancer. TLS can promote or inhibit the growth of PHC depending on their location, and although available findings are controversial, they suggest that TLS have a protective role in PHC tissues and a non-protective role in paracancerous tissues.

In addition, the cellular composition of TLS can also influence the outcome of PHC. As an immunity marker, TLS can act as a marker of immunotherapy to predict its effect and help to identify patients who will respond well to immunotherapy. Modulation of TLS formation through the use of chemokines/cytokines, immunotherapy, or induction of high endothelial vein to interfere with tumor growth has been studied extensively in PHC and other cancers.

In addition, new tools such as genetic interventions, cellular crosstalk, preoperative radiotherapy, and advances in materials science have been shown to influence the prognosis of malignant tumors by modulating TLS production. These can also be used to develop PHC treatment.

论文信息

作者
Jia W、Zhang T、Yao Q、Li J、Nie Y、Lei X、Mao Z、Wang Y
第一作者单位
Xi'an Medical University, Xi'an, China.China
通讯作者单位
Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.China
文献类型
综述 · 非美国政府资助研究
期刊
Frontiers in immunology2022
原文标识
PubMed 35844587 · DOI 10.3389/fimmu.2022.870458